GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » COGS-to-Revenue

Abaxis (Abaxis) COGS-to-Revenue : 0.45 (As of Mar. 2018)


View and export this data going back to 1992. Start your Free Trial

What is Abaxis COGS-to-Revenue?

Abaxis's Cost of Goods Sold for the three months ended in Mar. 2018 was $30.6 Mil. Its Revenue for the three months ended in Mar. 2018 was $67.9 Mil.

Abaxis's COGS to Revenue for the three months ended in Mar. 2018 was 0.45.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Abaxis's Gross Margin % for the three months ended in Mar. 2018 was 54.96%.

Abaxis COGS-to-Revenue Historical Data

The historical data trend for Abaxis's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis COGS-to-Revenue Chart

Abaxis Annual Data
Trend Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.46 0.44 0.45 0.45

Abaxis Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.45 0.45 0.46 0.45

Abaxis COGS-to-Revenue Calculation

Abaxis's COGS to Revenue for the fiscal year that ended in Mar. 2018 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=111.091 / 244.7
=0.45

Abaxis's COGS to Revenue for the quarter that ended in Mar. 2018 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=30.59 / 67.918
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abaxis  (NAS:ABAX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Abaxis's Gross Margin % for the three months ended in Mar. 2018 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 30.59 / 67.918
=54.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Abaxis COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abaxis's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Abaxis (Abaxis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » COGS-to-Revenue
Comparable Companies
NVTA MYGN NSE:LALPATHLAB SZSE:300244 NRC SZSE:300463 SZSE:300685 BEAT TSE:4544 SZSE:300482 SHSE:603127 TSE:4694 NEO SZSE:300406 MEDP OPK QDEL BOM:542650 RDNT CDNA
Traded in Other Exchanges
N/A
Address
Website
http://www.abaxis.com
Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.
Executives
Richard Bastiani director C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr officer: CFO and VP of Finance C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson director, officer: CEO & Board Chairman C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020